Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

被引：0

作者：

Sayani, Shermin ^{[1
]}

Iqbal, Omer ^{[1
]}

Hoppensteadt, Debra ^{[1
]}

Fareed, Jawed ^{[1
]}

机构：

[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 48 条

[41] Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders
Philip N. Patsalos
Clinical Pharmacokinetics, 2013, 52 : 1045 - 1061
[42] Four-factor prothrombin complex concentrate (4F-PCC) reverses bleeding associated with new oral anticoagulants (NOAC) dabigatran, rivaroxaban, edoxaban and apixaban in a rabbit model of acute bleeding
Herzog, E.
Kaspereit, F.
Krege, W.
Mueller-Cohrs, J.
Doerr, B.
Niebl, P.
Gerhard, D.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 903 - 903
[43] Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials
Kakkos, S. K.
Kirkilesis, G. I.
Tsolakis, I. A.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2014, 48 (05) : 565 - 575
[44] Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis (vol 11, e0160064, 2016)
Cohen, A. T.
Hamilton, M.
Bird, A.
Mitchell, S. A.
Li, Xiaoyan
Horblyuk, R.
Batson, S.
PLOS ONE, 2016, 11 (09):
[45] Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups
Lip, Gregory Y. H.
Mitchell, Stephen A.
Liu, Xianchen
Liu, Larry Z.
Phatak, Hemant
Kachroo, Sumesh
Batson, Sarah
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 204 : 88 - 94
[46] Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons
Hurst, K. V.
Lee, R.
Milosevic, I.
Handa, A.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2015, 50 (01) : 126 - 127
[47] Re: 'Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'
Spanos, K.
Giannoukas, A. D.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2015, 49 (03) : 353 - 353
[48] Poor concordance among drug compendia for proposed interactions between enzyme-inducing antiepileptic drugs and direct oral anticoagulants
Acton, Emily K.
Willis, Allison W.
Gelfand, Michael A.
Kasner, Scott E.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (11) : 1534 - 1538

← 1 2 3 4 5 →